Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Bone Marrow Sampling and Transplants

Bone Marrow Sampling and Transplants

Bone marrow transplant is a potential cure for several diseases, including cancer and specific genetic disorders. Notably, this procedure is applicable for patients suffering from aplastic anemia, certain types of leukemia, severe combined immunodeficiency disease (SCID), Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, thalassemia, sickle-cell disease, and certain cancers.
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Suicidal Ideation Experienced by Long-Term Survivors of Blood or Marrow Transplantation: A Blood or Marrow Transplant Survivor Study Report.

Transplantation and cellular therapy·2026

Same author

Total body irradiation and smoking interact to increase lung cancer risk after blood or marrow transplantation.

Blood advances·2026

Same author

Long-term health outcomes in older recipients of blood or marrow transplantation: a report from the BMTSS.

Blood advances·2026

Same author

Annual household income and chronic pulmonary conditions in long-term survivors of blood or marrow transplantation: a BMTSS report.

BMC pulmonary medicine·2025

Same author

Correction: Non-cryopreserved autologous peripheral blood stem cell transplantation for multiple myeloma and lymphoma in countries with limited resources: practice considerations from the Worldwide Network for Blood and Marrow Transplantation.

Bone marrow transplantation·2025

Same author

Smoking cessation among blood or marrow transplant Survivors: a BMTSS Report.

Bone marrow transplantation·2025

Search research articles

Related Experiment Video

Updated: Feb 27, 2026

Induction of Alloantigen-specific Anergy in Human Peripheral Blood Mononuclear Cells by Alloantigen Stimulation with Co-stimulatory Signal Blockade

Induction of Alloantigen-specific Anergy in Human Peripheral Blood Mononuclear Cells by Alloantigen Stimulation with Co-stimulatory Signal Blockade

Published on: March 14, 2011

Reduced-intensity versus myeloablative allogeneic transplantation.

Daniel J Weisdorf¹

¹University of Minnesota, Department of Medicine, Division of Hematology, Oncology and Transplantation, 420 Delaware Street SE, MMC 480, Minneapolis, MN 55455, United Sates.

Hematology/Oncology and Stem Cell Therapy

|June 23, 2017

Summary

Allotransplantation uses cytoreduction and graft-versus-leukemia (GVL) responses to cure patients by eliminating residual disease. Balancing conditioning intensity and immunosuppression is crucial for managing toxicities, preventing relapse, and achieving disease-free survival.

Keywords:

Conditioning intensity Graft versus leukemia Myeloablative Reduced intensity Stem cell transplantation

More Related Videos

Busulfan as a Myelosuppressive Agent for Generating Stable High-level Bone Marrow Chimerism in Mice

Busulfan as a Myelosuppressive Agent for Generating Stable High-level Bone Marrow Chimerism in Mice

Published on: April 1, 2015

Bone Marrow Transplantation Platform to Investigate the Role of Dendritic Cells in Graft-versus-Host Disease

Bone Marrow Transplantation Platform to Investigate the Role of Dendritic Cells in Graft-versus-Host Disease

Published on: March 17, 2020

Related Experiment Videos

Last Updated: Feb 27, 2026

Induction of Alloantigen-specific Anergy in Human Peripheral Blood Mononuclear Cells by Alloantigen Stimulation with Co-stimulatory Signal Blockade

Induction of Alloantigen-specific Anergy in Human Peripheral Blood Mononuclear Cells by Alloantigen Stimulation with Co-stimulatory Signal Blockade

Published on: March 14, 2011

Busulfan as a Myelosuppressive Agent for Generating Stable High-level Bone Marrow Chimerism in Mice

Busulfan as a Myelosuppressive Agent for Generating Stable High-level Bone Marrow Chimerism in Mice

Published on: April 1, 2015

Bone Marrow Transplantation Platform to Investigate the Role of Dendritic Cells in Graft-versus-Host Disease

Bone Marrow Transplantation Platform to Investigate the Role of Dendritic Cells in Graft-versus-Host Disease

Published on: March 17, 2020

Area of Science:

Hematology
Immunology
Oncology

Background:

Allotransplantation cures cancers via cytoreduction and graft-versus-leukemia (GVL) alloresponse, eliminating residual disease.
Conditioning intensity impacts toxicities and non-relapse mortality, while tumor sensitivity to GVL affects relapse rates.

Purpose of the Study:

To explore the interplay between conditioning intensity, immunosuppression, and graft effectiveness in allotransplantation.
To optimize strategies for balancing treatment toxicities and antineoplastic efficacy for improved patient outcomes.

Main Methods:

Analysis of factors influencing allotransplantation outcomes, including conditioning regimens and immunosuppression protocols.
Evaluation of patient performance status and comorbidities in relation to graft tolerance and efficacy.

Main Results:

Conditioning intensity is a key determinant of toxicities and non-relapse mortality.
Tumor sensitivity to the GVL response is critical for preventing relapse.
Intense immunosuppression, while necessary for engraftment and preventing graft-versus-host disease, can limit graft potency and antineoplastic capacity.

Conclusions:

Achieving successful allotransplantation requires careful balancing of conditioning intensity and immunosuppression.
Optimizing graft effectiveness and minimizing toxicities are essential for maximizing disease-free survival in patients undergoing allotransplantation.